April 26, 2019
Twelve-year retrospective study demonstrates efficacy of peptide receptor radionuclide therapy
Reston, VA—A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy (PRRT) for malignant neuroendocrine tumors demonstrates the long-term effectiveness of this treatment, which also allows patients to maintain a high quality of life. The study is featured in the April issue of The Journal of Nuclear Medicine.
While PRRT has been used for more than 20 years to treat patients with inoperable or metastatic somatostatin receptor–positive tumors, knowledge of long-term outcomes has been limited. A number of clinical studies have demonstrated PRRT’s efficacy, and the overall response rate (including complete response, partial response, minor response, and stable disease) is about 70-80 percent for the two most commonly used radiopharmaceuticals: yttrium-90 (90Y)-DOTATOC (best suited for treating larger tumors) and lutetium-177 (177Lu)-DOTATATE (preferred for smaller tumors). For patients who respond to PRRT, the prognosis is generally favorable, with a median time to disease progression of three to four years.
This study included 44 patients (27 men and 17 women) with advanced tumors and enhanced somatostatin receptor expression. Mean age at initial diagnosis was 60 years (age range of 40 to 84). Median follow-up was 80 months. For 177Lu-PRRT, the mean number of cycles administered was 5.3 ± 2.5; for 90Y-PRRT, the mean number of cycles administered was 5.5 ± 2.6.
Median overall survival was 79 months, but 32 percent of the patients (14 of the 44 patients—6 men and 8 women) were still alive more than 12 years after starting PRRT. Progressive disease occurring early after therapy began resulted in a poor prognosis, while women and patients with no more than two tumor sites seemed to benefit the most from PRRT.
“This study clearly demonstrates the long-term efficacy of PRRT over more than a decade in patients with metastatic tumor disease of neuroendocrine origin,” explain Michael Gabriel, MD, and Irene J. Virgolini, MD, of the Department of Nuclear Medicine at the Medical University of Innsbruck in Austria. They add that the research shows, “PRRT can be repeatedly used with limited side effects. From this perspective, a relatively stable tumor situation can be achieved over many years in a large number of patients. None of the patients who were still alive at the end of the observation period were dialysis-dependent, and most of the patients showed a still very high KPI (key performance indicator), which underlines the positive effect of PRRT in terms of the quality of life.”
Gabriel and Virgolini also point out the value of molecular imaging in therapeutic decision-making and, looking ahead, recommend “new prospective studies combining the nuclear medicine therapy approach with other therapeutic modalities to further increase efficiency.”
FIGURE: Graph showing that only 18 percent of patients initially treated with 90Y-therapy were alive after 12 years, whereas nearly 48 percent of patients in the 177Lu group were alive. Credit: M Gabriel and IJ Virgolini, et al., Department of Nuclear Medicine, Medical University of Innsbruck, Austria.
Authors of “Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy” include Michael Gabriel, Medical University of Innsbruck, Innsbruck, Austria, and Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria; Bernhard Nilica and Irene J. Virgolini, Medical University of Innsbruck, Innsbruck, Austria; and Bernhard Kaiser, Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria.
For more information or to schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or firstname.lastname@example.org. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
Dr. Virgolini explains the research in a video on The JNM Podcast.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.